ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,064.20
0.91%
US Tech 100
17,182.00
0.62%
다우존스 지수
38,225.66
0.00%
Bitcoin
59,280.45
0.27%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Kymera Therapeutics Inc (KYMR)

  7. Kymera Therapeutics Inc (KYMR) 뉴스

KYMR Kymera Therapeutics Inc

36.30
0.00 (0.00%)
시간외 단일가
최종 업데이트: 20:00:05
15분 지연
기업명 주식 심볼 시장 주식 타입
Kymera Therapeutics Inc KYMR 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.00 0.00% 36.30 20:00:05
개장가 저가 고가 종가 전일 종가
36.30
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
02/05/202420:00GLOBEKymera Therapeutics Announces First Quarter 2024 Financial..
25/04/202420:00GLOBEKymera Therapeutics to Report First Quarter 2024 Financial..
08/04/202420:00GLOBEKymera Therapeutics Announces Scientific Presentations at..
09/03/202400:00GLOBEKymera Therapeutics Presents Preclinical Data for STAT6 and..
05/03/202408:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/03/202408:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/03/202408:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/03/202407:50EDGAR2Form 144 - Report of proposed sale of securities
05/03/202407:47EDGAR2Form 144 - Report of proposed sale of securities
28/02/202421:00GLOBEKymera Therapeutics to Participate in Upcoming March..
28/02/202406:22EDGAR2Form 144 - Report of proposed sale of securities
22/02/202421:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/02/202421:10EDGAR2Form 8-K - Current report
22/02/202421:00GLOBEKymera Therapeutics Announces Fourth Quarter and Full Year..
15/02/202421:00GLOBEKymera Therapeutics to Report Fourth Quarter and Full Year..
10/02/202409:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202406:22EDGAR2Form 144 - Report of proposed sale of securities
31/01/202421:00GLOBEKymera Therapeutics to Present in Fireside Chat at the..
09/01/202423:17GLOBEKymera Therapeutics Outlines Key 2024 Objectives and..
09/01/202423:15GLOBEKymera Therapeutics Announces Closing of Upsized $275..
06/01/202406:11EDGAR2Form 8-K - Current report
06/01/202406:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/01/202420:00GLOBEKymera Therapeutics Announces Pricing of $275 Million Public..
05/01/202406:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/01/202406:01GLOBEKymera Therapeutics Announces Proposed Public Offering
04/01/202421:08EDGAR2Form 8-K - Current report
04/01/202421:00GLOBER&D Day Highlights Kymera’s Immunology Strategy and Emerging..
03/01/202407:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/01/202421:00GLOBEKymera Therapeutics to Present at the 42nd Annual J.P...
13/12/202321:00GLOBEKymera Therapeutics to Host Virtual Immunology R&D Day on..
11/12/202311:00GLOBEKymera Therapeutics Presents Interim Results from STAT3..
07/12/202321:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
14/11/202301:00GLOBEKymera Therapeutics Announces Publication of Phase 1 Trial..
07/11/202308:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202322:15EDGAR2Form 8-K - Current report
02/11/202322:00GLOBEKymera Therapeutics to Present New Clinical Data from the..
02/11/202320:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202320:10EDGAR2Form 8-K - Current report
02/11/202320:00GLOBEKymera Therapeutics Announces Third Quarter 2023 Financial..
01/11/202320:00GLOBEKymera Therapeutics to Participate in Upcoming November..
27/10/202320:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
26/10/202320:00GLOBEKymera Therapeutics to Report Third Quarter 2023 Financial..
16/10/202320:00GLOBEKymera Therapeutics Presents Preclinical Data Demonstrating..
18/09/202320:00GLOBEKymera Therapeutics Receives U.S. FDA Fast Track Designation..
09/08/202305:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/08/202320:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/08/202320:10EDGAR2Form 8-K - Current report
03/08/202320:00GLOBEKymera Therapeutics Announces Second Quarter 2023 Financial..
27/07/202320:00GLOBEKymera Therapeutics to Report Second Quarter 2023 Financial..
22/06/202322:21DJNKymera Therapeutics Gets Orphan-Drug Status for Leukemia..

최근 히스토리

NASDAQ
KYMR
Kymera Therapeutics
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유